Bicycle Therapeutics (BCYC) FCF Margin (2018 - 2026)
Bicycle Therapeutics (BCYC) reported FCF Margin of 7512.74% for Q1 2026, down 664099.0% on a YoY basis from N/an in Q1 2025, and down 17986.02% quarter-over-quarter from 41.54% in Q4 2025.
Bicycle Therapeutics (BCYC) FCF Margin (2018 - 2026) Analysis & Trends
Bicycle Therapeutics has reported FCF Margin for 9 years, with the latest figure at 7512.74% in Q1 2026.
- For the quarter ending Q1 2026, FCF Margin fell 664099.0% year-over-year to 7512.74%; the trailing twelve-month figure through Mar 2026 stood at 364.89% (up 34288.0% YoY), and the FY2025 full-year result was 347.21%, up 12326.0% from the prior year.
- FCF Margin for Q1 2026 stood at 7512.74%, down from 41.54% in the prior quarter.
- The five-year high for FCF Margin was 296.74% in Q2 2023, with the low at 7512.74% in Q1 2026.
- Historically, FCF Margin has averaged 1056.63% across 5 years, with a median of 612.3% in 2025.
- Annual changes were most pronounced in 2025 — FCF Margin surged 89245 bps — and 2026, when it plunged 664099 bps.
- Bicycle Therapeutics' FCF Margin stood at 378.06% in 2022, then slumped by 135 bps to 887.99% in 2023, then surged by 70 bps to 263.32% in 2024, then jumped by 84 bps to 41.54% in 2025, then plunged by 17986 bps to 7512.74% in 2026.
- The last three FCF Margin figures came in at 7512.74% (Q1 2026), 41.54% (Q4 2025), and 612.3% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -3.98% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Bicycle Therapeutics | 278.04 Mn | 278.04 Mn | - | -7,512.74% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7,512.74% |
| Dec 31, 2025 | -41.54% |
| Sep 30, 2025 | -612.30% |
| Jun 30, 2025 | -2,509.73% |
| Mar 31, 2025 | -871.75% |
| Dec 31, 2024 | -263.32% |
| Sep 30, 2024 | -1,504.75% |
| Jun 30, 2024 | -481.22% |
| Mar 31, 2024 | -681.55% |
| Dec 31, 2023 | -887.99% |
| Sep 30, 2023 | -28.53% |
| Jun 30, 2023 | 296.74% |
| Mar 31, 2023 | -990.81% |
| Dec 31, 2022 | -378.06% |
| Sep 30, 2022 | -291.28% |
| Jun 30, 2022 | -396.79% |
| Mar 31, 2022 | -807.15% |
| Dec 31, 2021 | -718.88% |
| Sep 30, 2021 | 497.32% |
| Jun 30, 2021 | -702.58% |